Welcome to our dedicated page for Cytomx Therapeutics news (Ticker: CTMX), a resource for investors and traders seeking the latest updates and insights on Cytomx Therapeutics stock.
CytomX Therapeutics Inc (CTMX) is a clinical-stage biopharmaceutical pioneer developing conditionally activated cancer therapies through its probody technology platform. This dedicated news hub provides investors and researchers with essential updates on clinical advancements, strategic collaborations, and therapeutic innovations in oncology.
Access real-time updates on CTMX's probody-based candidates, including antibody drug conjugates and T-cell engagers. The platform centralizes critical developments such as trial milestones, partnership expansions with industry leaders like Astellas and Merck, and financial disclosures - all vital for informed analysis of this innovative oncology company.
Key content categories include clinical program progress, regulatory updates, scientific presentations, and corporate financial results. Each update is curated to highlight how CTMX's tumor-activated therapies aim to improve cancer treatment safety profiles while maintaining therapeutic efficacy.
Bookmark this page for streamlined access to verified CTMX developments. Regularly updated with official press releases and objective reporting, it serves as your primary resource for tracking advancements in conditionally activated cancer immunotherapies.
CytomX Therapeutics (CTMX) announced the presentation of preclinical data on a conditionally activated interferon alpha-2b at the SITC 2021 Annual Meeting from November 12-14, 2021. The data highlights the safety and anti-cancer activity of this treatment, showcasing the potential of CytomX's Probody® technology platform. This innovative approach aims to minimize toxicity while enhancing therapeutic efficacy against cancer. With a robust clinical pipeline, CytomX is focused on developing safer, more effective therapies for patients.
CytomX Therapeutics, Inc. (Nasdaq: CTMX) announced their upcoming third quarter 2021 financial results on November 4, 2021, following U.S. market closure. A conference call at 5:00 p.m. ET will provide insights into the results and corporate updates. CytomX is focused on developing conditionally activated therapeutics via their Probody® technology platform, aiming to improve cancer therapy effectiveness while minimizing toxicity. The company collaborates with industry leaders like AbbVie and Bristol Myers Squibb, having a pipeline with multiple assets in Phase 2 clinical trials.
CytomX Therapeutics (Nasdaq: CTMX), a biopharmaceutical company focused on oncology, announced the grant of stock options to six new employees on October 15, 2021. A total of 177,000 shares were offered at an exercise price of $5.14, matching the closing price on the grant date. The options are part of the 2019 Employment Inducement Incentive Plan, approved by the board in August 2020. CytomX specializes in conditionally activated therapeutics, employing its Probody® technology platform, to target cancer with minimized toxicity.
CytomX Therapeutics (Nasdaq: CTMX) has appointed Alan Ashworth, Ph.D., a distinguished cancer researcher, to its board of directors. Dr. Ashworth, known for identifying the BRCA2 gene and developing PARP inhibitors, brings extensive experience to advance CytomX's clinical pipeline. President Sean McCarthy emphasized Dr. Ashworth's expertise in translational sciences will be valuable as the company targets key Phase 2 milestones. CytomX focuses on conditionally activated therapeutics using its Probody technology to improve cancer treatment outcomes while minimizing toxicity.
CytomX Therapeutics, Inc. (Nasdaq: CTMX) announced the granting of stock options to nine new employees, totaling 157,200 shares at an exercise price of $4.97, matching the closing price on September 15, 2021. These options were issued under the 2019 Employment Inducement Incentive Plan to attract new talent. CytomX is focused on developing conditionally activated therapeutics for cancer treatment based on its Probody technology, with significant collaborations with major firms like AbbVie and Bristol Myers Squibb, and a portfolio featuring multiple candidates in clinical trials.
CytomX Therapeutics (Nasdaq: CTMX) announced that Sean McCarthy, D.Phil., will participate in a virtual fireside chat during the H.C. Wainwright 23rd Annual Global Investment Conference from September 13-15, 2021.
The pre-recorded session will be available for on-demand viewing starting September 13 at 7:00 a.m. ET on CytomX’s website, with a 90-day archive afterwards. CytomX is developing Probody therapeutics aimed at treating cancer, focusing on minimizing toxicity while enhancing treatment efficacy.
CytomX Therapeutics (CTMX) announced the grant of stock options to seven new employees for a total of 172,600 shares at $4.81 each, reflecting the closing price on August 16, 2021. This grant, made under the 2019 Employment Inducement Incentive Plan, aims to attract new talent. CytomX, an oncology-focused biopharmaceutical firm, specializes in conditionally activated antibody therapeutics using its Probody® technology platform to target cancer effectively while minimizing toxicity. The company collaborates with major pharmaceutical partners and has a clinical pipeline advancing towards Phase 2 studies.
CytomX Therapeutics (CTMX) reported its Q2 2021 financial results, showing $16 million in revenue, consistent with Q2 2020. Cash reserves totaled $366 million, up from $316 million at year-end 2020. The company continues to advance its Probody therapeutics pipeline with ongoing Phase 2 studies for leading drug candidates CX-2009 and CX-2029. Initial data from CX-2009, impacted by COVID-19, is now expected in 2022, while data from CX-2029 is anticipated in Q4 2021. Five peer-reviewed publications in 2021 highlight CytomX's scientific advancements.
CytomX Therapeutics (Nasdaq: CTMX) announced significant findings related to its investigational drug pacmilimab (CX-072) in three peer-reviewed publications. Pacmilimab exhibited single-agent activity in advanced solid tumors, notably in metastatic triple-negative breast cancer (TNBC). It demonstrated potential for combination therapies with ipilimumab, addressing limitations of conventional immune checkpoint inhibitors. The overall objective response rate (ORR) in patients treated was 12%, with a disease control rate of 42%. Results suggest pacmilimab may provide a safer alternative with reduced toxicity.
CytomX Therapeutics (Nasdaq: CTMX) announced that CEO Sean McCarthy will participate in two upcoming virtual investor conferences. The BTIG 5th Virtual Biotechnology Conference is scheduled for August 9, 2021, at 1:00 p.m. ET, followed by the 2021 Wedbush PacGrow Healthcare Virtual Conference on August 10, 2021, with a panel discussion at 1:10 p.m. ET. CytomX focuses on developing Probody therapeutics, which are designed to selectively target tumors and minimize toxicity. The company collaborates with leaders in the biotechnology sector and has a robust clinical pipeline.
FAQ
What is the current stock price of Cytomx Therapeutics (CTMX)?
What is the market cap of Cytomx Therapeutics (CTMX)?
